Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXINASDAQ:ENTONASDAQ:SCNINASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.21-26.6%$0.24$0.17▼$3.93$663K-0.09130,662 shs2,392 shsENTOEntero Therapeutics$0.49-10.9%$0.41$0.19▼$2.29$2.34M0.85716,100 shs239,378 shsSCNIScinai Immunotherapeutics$2.22-4.7%$2.53$1.90▼$8.92$2.22M2.1361,904 shs55,231 shsSPRBSpruce Biosciences$0.07-3.6%$0.11$0.06▼$0.67$3.27M2.38716,648 shs196,343 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-26.59%-19.92%-13.25%-75.45%-94.03%ENTOEntero Therapeutics-11.02%-5.71%+17.30%+1.72%-76.31%SCNIScinai Immunotherapeutics-4.72%-12.94%-17.78%-33.63%-17.47%SPRBSpruce Biosciences-3.61%+16.90%+20.48%-77.71%-88.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXIAvenue Therapeutics1.8211 of 5 stars0.03.00.04.61.50.01.9ENTOEntero Therapeutics0.2335 of 5 stars0.02.00.00.01.90.00.6SCNIScinai Immunotherapeutics0.6412 of 5 stars0.03.00.00.01.82.50.0SPRBSpruce Biosciences2.4106 of 5 stars3.03.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AENTOEntero Therapeutics 0.00N/AN/AN/ASCNIScinai Immunotherapeutics 0.00N/AN/AN/ASPRBSpruce Biosciences 2.00Hold$1.752,242.70% UpsideCurrent Analyst Ratings BreakdownLatest ATXI, SPRB, SCNI, and ENTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$1.50 ➝ $0.50(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AENTOEntero TherapeuticsN/AN/AN/AN/A$2.31 per shareN/ASCNIScinai Immunotherapeutics$658K3.37N/AN/A($9.84) per share-0.23SPRBSpruce Biosciences$4.91M0.64N/AN/A$1.88 per share0.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M$18.350.01∞N/AN/A-471.57%-296.50%8/7/2025 (Estimated)ENTOEntero Therapeutics-$15.80MN/A0.00∞N/AN/A-87.06%-12.01%N/ASCNIScinai Immunotherapeutics-$6.50M-$9.57N/A∞N/AN/AN/A-30.48%7/1/2025 (Estimated)SPRBSpruce Biosciences-$47.92M-$1.32N/AN/AN/A-555.23%-62.10%-47.49%8/11/2025 (Estimated)Latest ATXI, SPRB, SCNI, and ENTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025ENTOEntero TherapeuticsN/A-$0.21N/A-$0.28N/AN/A5/7/2025Q4 2024SCNIScinai ImmunotherapeuticsN/A-$10.40N/A-$10.40N/A$0.21 million4/15/2025Q4 2024SPRBSpruce Biosciences-$0.20-$0.57-$0.37-$0.57$0.50 million$0.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/ASCNIScinai ImmunotherapeuticsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70ENTOEntero TherapeuticsN/A5.345.34SCNIScinai Immunotherapeutics0.061.161.16SPRBSpruce Biosciences0.015.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%ENTOEntero Therapeutics12.30%SCNIScinai Immunotherapeutics58.41%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics1.80%ENTOEntero Therapeutics0.49%SCNIScinai Immunotherapeutics60.90%SPRBSpruce Biosciences6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.18 million2.02 millionNot OptionableENTOEntero Therapeutics94.77 million4.73 millionN/ASCNIScinai Immunotherapeutics201.00 million334,000Not OptionableSPRBSpruce Biosciences2042.23 million37.54 millionOptionableATXI, SPRB, SCNI, and ENTO HeadlinesRecent News About These CompaniesSpruce Biosciences gets conditional approval to resume trading on Nasdaq Capital MarketJune 13 at 8:21 AM | msn.comSpruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital MarketJune 12 at 8:42 AM | finance.yahoo.comSpruce Biosciences’ Compliance Plan Accepted by NasdaqJune 12 at 8:34 AM | tipranks.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Recommendation of "Hold" by AnalystsJune 5, 2025 | americanbankingnews.comSpruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacksMay 7, 2025 | investing.comSpruce Biosciences Inc Ordinary SharesMay 6, 2025 | morningstar.comSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 6, 2025 | finance.yahoo.comSpruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease AssetApril 28, 2025 | biospace.comSpruce halves head count, narrowing focus to get ex-BioMarin drug to FDAApril 28, 2025 | fiercebiotech.comSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17, 2025 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17, 2025 | insidermonkey.comSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)April 15, 2025 | standard-journal.comWith BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15, 2025 | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15, 2025 | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comSpruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying ValueFebruary 5, 2025 | bovnews.comHold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic UncertaintiesDecember 16, 2024 | markets.businessinsider.comSpruce Biosciences (SPRB) Upgraded to Buy: Here's WhyDecember 13, 2024 | zacks.comJMP Securities Downgrades Spruce Biosciences (SPRB)December 12, 2024 | msn.comSpruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubtDecember 11, 2024 | fiercebiotech.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATXI, SPRB, SCNI, and ENTO Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.21 -0.08 (-26.59%) As of 06/13/2025 02:00 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Entero Therapeutics NASDAQ:ENTO$0.49 -0.06 (-10.85%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.48 -0.01 (-2.10%) As of 06/13/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Scinai Immunotherapeutics NASDAQ:SCNI$2.22 -0.11 (-4.72%) Closing price 06/13/2025 03:55 PM EasternExtended Trading$2.26 +0.04 (+1.80%) As of 06/13/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Spruce Biosciences NASDAQ:SPRB$0.07 0.00 (-3.61%) As of 06/13/2025 03:22 PM EasternSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
